Sabah Geriatric Conference 2023 2 6 - 2 7 t h O c t o b e r 2 0 2 3 S a b a h In t e r n a tial C o n v e n tio n C e n t e r Active Aging: Never Past your Prime
Dear Colleagues and friends, It is with great pleasure that we extend a warm welcome to all esteemed guests, speakers, and attendees of the Sabah Geriatric Conference 2023. In the spirit of "Active Ageing - Never Past Your Prime," this conference aims to explore and celebrate the myriad ways individuals continue to thrive, contribute, and redefine what it means to age gracefully. As we gather to share insights, research, and experiences, let us collectively embrace the power of resilience, the wisdom of years, and the joy of staying actively engaged in our communities. May this conference inspire new perspectives, foster meaningful connections, and catalyze positive change in geriatric care. Together, let us embark on a journey to ensure that every stage of life is an opportunity for growth and fulfillment. Thank you for being part of this transformative event. Wishing you a conference filled with discovery and collaboration! Warmest regards, Dr Gordon Pang Hwa Mang Organizing Chair Sabah Geriatric Conference 2023 Welcome Message
pn Organizing Committee Dr Gordon Pang Hwa Mang Dr Ho Hee Kheen Dr Wong Yee Ling Sr Ida Rosyany Abdulamit, Sr Naney Tukijan Mr Daryl Louis Aloysius Dr Woo Fui Bee Dr Wong Wei Xiang Dr Ang Jie Ying Dr Ahmad Zulkhairi Saadon Dr Liew Jun Yong Ms Liew Sue Khin Dr Syuhada Binti Zakaria Dr Norfazalina Abdurakman Dr Tharshinii A/L Devaraj Dr Katarina Choo Shin Yee Dr Ong Xin Wei Sn Feridah Baninus Sn Syltrina Mijia Sn Atika Supeki Sn Rohilin Justa Organizing Chairperson 1st Co Chairperson 2nd Co Chairperson Secretary Assistant Secretary Treasurer IT support Logistics Team Registration Team Sponsorship Team Registration booth
pn Organizing Committee Sn Amri Zinin Sn Rozie Simon Sn Noraniza Karim PPK Sylecia Jusilin PPK Mohd Abd Barr Limon Sr Naney Tukijan Ms Liew Sue Khin Sn Ainneros Soguluh Sn Emely Kaing Sn Dg Illani Awg Ahmad Sah Sn Siti Norazryna Ilyas Sn Bibi Alisha Lee Abdullah Pn Nornadira binti Muhaizan (UKK) En Suhaime bin Sahirul Photo Booth Set up Souvenir Team Protocol & Media
For Healthcare Professionals Only. Full prescribing information available upon request from: Novartis Corporation (Malaysia) Sdn Bhd (197101000541) Level 18, Imazium, No. 8, Jalan SS21/37 Damansara Uptown, 47400 Petaling Jaya, Selangor, Malaysia Tel: +6 03-7682 7777 Fax: +6 03-7682 7000 ENT.LBM.00/MY2204226399 Scan QR Code to access ENTRESTO® Product Information Now is the time to reshape the failing heart *The cohort included 108 patients, only 48 of which were ACEi/ARB naive.1 IMPROVE HEART FUNCTION START WITH OR SWITCH TO ENTRESTO® AS EARLY AS POSSIBLE TO RAPIDLY REVERSE CARDIAC REMODELLING AND REDUCE RATES OF HF HOSPITALIZATIONS AND CV DEATHS VS ACEi1,2 START EARLY FOR EXTRA BENEFIT INCREASED LVEF BY ADDITIONAL AFTER 12 MONTHS1 ABSOLUTE INCREASE IN LVEF WHEN ENTRESTO IS STARTED FIRSTLINE*1 5.2% AFTER 6 MONTHS 9.4% 7% LVEF=left ventricular ejection fraction; ACEi=angiotensin-converting enzyme inhibitor; ARB=angiotensin receptor blocker; HF=heart failure; CV=cardiovascular. References: 1. Januzzi JL Jr et al. JAMA. 2019;322(11):1085-1095. 2. McMurray JJV et al. N Engl J Med. 2014;371(11)993-1004.
Day 1: 26th October 2023 (am) 0730 Registration 0800 Opening Ceremony Datuk Dr Kahar Abd Asis, Dr Irene Chau 0900 Direction of Geriatric Service in Malaysia Dr Yau Weng Keong, Consultant Geriatrician 0945 Anemia in the Eldery Dr Lily Wong, Consultant Hematologist, HQE 1015 Tea Symposium: Sponsored by Bayer Protecting the Aging Patients with AF- is anticoagulation safe Dr Gordon Pang, Consultant Geriatrician, HQE 1045 Heart Disease in the Elderly; Cardiogeriatrics Dr Liew Houng Bang, Consultant Cardiologist, HQE 1115 Incontinence Mr Ooi Chin Chuan, Consultant Urologist, HQE 1145 Common Issues in Hospitalized Elderly Dr Keng Jun Ni, Consultant Geriatrician, Hospital Seberang Jaya 1215 Comprehensive Geriatrics Assessment Dr Keng Jun Ni, Consultant Geriatrician, Hospital Seberang Jaya 1245 Lunch Symposium : Sponsored by Novartis Regression of Heart Failure in the Golder Years Dr Gordon Pang, Consultant Geriatrician, HQE pn Programme
Breakout 1 Breakout 2 1400 3F: Falls, Fracture, Frailty Dr Ling Jia Nee, Consultant Geriatrician, Hospital Umum Sarawak Nursing- Our Nurse, Our Future Sr Ida Rosyany 1420 Orthogeriatric Dr Gordon Pang, Consultant Geriatrican, HQE Physiotherapy- Role of PT in acute hospitalized elderly Mr Massni Sampit 1440 Forum: Orthogeriatrics with Case Presentation Moderator: Dr Gordon Pang Dr Ling Jia Nee (Geriatrician) Mr Aaron Paul (Orthopedic Surgeon) Dr Shazharn (Anaesthetist) Occupational Therapy - Driving Assessment in the Elderly Mr Alexander Robert 1500 Dietician - Nutrition Care for Older Adults Ms Ernetty Syakira Marhalim 1520 Speech Therapist - Dysphagia screening and management Ms Esther Tuin Day 1: 26th October 2023 (pm) pn Programme 1540 Tea Symposium: Sponsored by Pfizer Covid-19 Vaccination: What’s the way forward for our elderly population? Dr Lee Heng Gee, Consultant Infection Disease Physician, HQE Breakout 1 Breakout 2 1600 Challenges In elderly with Parkinson’s Disease Dr Chia Yuen Kang Consultant Neurologist, HQE Dentistry- Common dental Issues in elderly Dr Eileen Yap Ai Ling Special Needs Dentistry, HQE 1620 Q&A Q&A
* RRR was calculated as 1-HR by Bayer. REFERENCES: 1. Patel MR, et al. N Engl J Med. 2011;365:883–891. 2. Bansilal S, et al. Am Heart J. 2015;170:675–682.e8. 3. Yao X, et al. J Am Coll Cardiol. 2017;70:2621–2632. 4. Bonnemeier H, et al. Comparative safety and effein patients with non-valvular atrial brillation and renal disease – results from the RELOADED Study. ESOC 2019, 22–24 May; Milan, Italy. Abstract AS25-066. https://journals.sagepub.com/doi/full/10.1177/2396987319845581. 5. XarelPRESCRIBING INFORMATION Brand name of product Xarelto Film-Coated Tablets 10mg, 15mg & 20mg. Approved name of the active ingredient Each lm-coated tablet contains either 10 mg, 15mg or 20mg of rivaroxaban. Indiprevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Xarelto 15mg & 20mg is indicated for the prevention of stroke and systemic embolism in adult patients with nonvalvusuch as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT anadministration: Prevention of VTE in hip or knee replacement surgery: The recommended dose of XARELTO is a 10 mg tablet taken once daily, with or without food. The duration of treatment depends on the type of orthopaedic s610 hours after surgery provided that hemostasis has been established. Prevention of stroke and systemic embolism: The recommended dose is 20 mg once daily, which is also the recommended maximum dose In patients with mrecommended dose is 15 mg once daily; Treatment of DVT and PE and prevention of recurrent DVT and PE: The recommended dose for the initial treatment of acute DVT or PE is 15 mg twice daily for the rst three weeks followedand prevention of recurrent DVT and PE. A reduction of the dose from 20 mg once daily to 15 mg once daily should be considered if the patient’s assessed risk for bleeding outweighs the risk for recurrent DVT and PE. Contraindicatiohypersensitivity to rivaroxaban or any excipient; with clinically signi cant active bleeding; hepatic disease which is associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child Pugh B and C. XAbreast-feeding women for all strengths, or any lesion or condition if considered to be a signi cant risk of major bleeding; concomitant treatment with any other anticoagulant agent except under the circumstances of switching anticoagulanecessary to maintain an open central venous or arterial catheter. Special warnings and special precautions for use (10mg). Concomitant medication: Xarelto is not recommended in patients receiving concomitant systemic treatminhibitors which may lead to an increased bleeding risk. Renal impairment: Xarelto is to be used with caution in patients with moderate renal impairment (CrC: <50-30 mL/min) receiving co-medications leading to increased rivaroxabanwith caution in patients with CrC <3015 mL/min. No clinical data are available for patients with severe renal impairment (CrC <15 mL/min). Therefore use of Xarelto is not recommended in these patients. Hemorrhagic Risk: Xarelto shincreased bleeding risk such as:congenital or acquired bleeding disorders, uncontrolled severe arterial hypertension, current or recent gastrointestinal ulcerations, other gastrointestinal disease without active ulceration that can potentiahemorrhage, intraspinal or intracerebral vascular abnormalities, recent brain, spinal or ophthalmological surgery, vascular retinopathy, and bronchiectasis or history of pulmonary bleeding, Epidural/spinal anesthesia or puncture: Anthan 18 hours after the last administration of Xarelto. Xarelto should be administered at earliest 6 hours after the removal of the catheter. If traumatic puncture occurs the administration of Xarelto should be delayed for 24 hours, Surgeror surgical intervention is required, Xarelto10 mg should be stopped at least 24 hours before the intervention, if possible. Xarelto should be restarted as soon as possible after the invasive procedure or surgical intervention provided thehas been established. Women of child bearing potential: Women of child bearing potential should avoid becoming pregnant during treatment with rivaroxaban. Dermatological reactions: Serious skin reactions, including Stevens-Johave been reported during post-marketing surveillance Special warnings and special precautions for use (15 & 20mg): Haemorrhagic risk: As with other anticoagulants, patients taking Xarelto are to be carefully observed for signscaution in conditions with increased risk of haemorrhage. Xarelto administration should be discontinued if severe haemorrhage occurs. Patients with non-valvular atrial brillation who undergo PCI (percutaneous coronary intervelimited experience of a reduced dose of 15 mg Xarelto once daily (or 10 mg Xarelto once daily for patients with moderate renal impairment [creatinine clearance 30 – 49 ml/min]) in addition to a P2Y12 inhibitor for a maximum of 12 monwho require oral anticoagulation and undergo PCI with stent placement. Renal impairment: Xarelto is to be used with caution in patients with creatinine clearance 15 – 29 ml/min. Use is not recommended in patients with creatinine clemedicinal products: The use of Xarelto is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics or HIV protease inhibitors. Care is to be taken if patients are treated concomitantly with mediciwith prosthetic valves: Treatment with Xarelto is not recommended for these patients. Haemodynamically unstable PE patients or patients who require thrombolysis or pulmonary embolectomy: Xarelto is not recommended apatients with pulmonary embolism who are haemodynamically unstable or may receive thrombolysis or pulmonary embolectomy. Spinal/epidural anaesthesia or puncture: Prior to neuraxial intervention the physician should consideranticoagulated patients or in patients to be anticoagulated for thromboprophylaxis. For the removal of an epidural catheter at least 18 hours in young patients and 26 hours in elderly patients should elapse after the last administration ofat least 6 hours should elapse before the next rivaroxaban dose is administered. If traumatic puncture occurs the administration of rivaroxaban is to be delayed for 24 hours. Dosing recommendations before and after invasive procshould be stopped at least 24 hours before an invasive procedure or surgical intervention. Xarelto should be restarted as soon as possible after the invasive procedure or surgical intervention provided the clinical situation allows and adInformation about excipients: Xarelto contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase de ciency or glucose-galactose malabsorption should not take this medicinal product. Women obearing potential should avoid becoming pregnant during treatment with rivaroxaban. Elderly population: increasing age may increase haemorrhagic risk. Dermatological reactions: Serious skin reactions, including Stevens-Johnsonreported during post-marketing surveillance. Undesirable effects: Common adverse drug reactions reported include: Blood and the lymphatic system disorders: Anemia; Nervous system disorders Dizziness, headache. Eye disoHypotension, hematoma; Respiratory, thoracic and mediastinal disorders: Epistaxis, hemoptysis; Gastrointestinal disorders: Gingival bleeding, nausea, gastrointestinal tract hemorrhage, gastrointestinal and abdominal pains, dysSkin and subcutaneous tissue disorders: Pruritus, rash, ecchymosis, cutaneous and subcutaneous hemorrhage; Musculoskeletal, connective tissue and bone disorders: Pain in extremity; Renal and urinary disorders: Urogendisorders and administration site conditions: Fever, peripheral oedema, decreased general strength and energy; Investigations: Increase in transaminases; Injury, poisoning and postprocedural complications; Postprocedurafurther prescribing information, please contact Bayer Co. (M) Sdn Bhd, B-19-1 & B-19-2, The Ascent Paradigm, No. 1, Jalan SS 7/26A, Kelana Jaya, 47301 Petaling Jaya, Selangor. Subject to medical prescription. Date of text revFull prescribing information available upon request. Bayer Co. (Malaysia) Sdn Bhd. Protect what matters most for people like Encik Ahmad ®With Xarelto you can give him: • • • Protection against stroke and CV death1,2 Better observed renal function preservation vs VKAs3,4 The right dose, at the right time, for the right reason*,5 … and the chance to tell EXTRA ‘GRANDAD’ JOKES For healthcare professionals only. /2 25-03 & 25-04, Level 25, IMAZIUM. No 8, Jalan SS21/37, Damansara Uptown. 47400 Petaling Jaya, Selangor, Malaysia Tel: +60 3 7801 3162 Fax: +60 3 7886 3338 Web: https://www.bayer.com 052) Which of your patients with both NVAF and diabetes can Xarelto® help you protecPP-XAR-MY-0080-1 (
Day 2: 27th October 2023 0800 Delirium Dr Premala Subramaniam, Consultant Geriatrician, Hospital Permaisuri Bainun Ipoh 0830 Understanding Dementia “Never too early, never too late” Dr Peter Selestine, Consultant Geriatrician, KPJ Johor 0900 Medication management in the elderly Mr James Voo, Pharmacist, Hospital Duchess of Kent, Sandakan 0930 Tea Symposium: Sponsored by Pfizer Prespectives of VTE management among patient with comorbidities Dr Tan Jiun Liang, Consultant Respiratory Physician, UMMC 1000 Management of DM and Dyslipidemia in Elderly Dr Tee Hwee Ching, Consultant Endocrinologist, HQEII 1030 Geriatric Social Work: The Role of Social Worker in Elderly Care Ms Tan Hui Sin, Medical Social Worker, HQE 1100 Community Geriatrics Dr Noor Harzana Harrun, Family Medicine Consultant, KK Pandamaran, Klang 1130 Lucky Draw and Closing Ceremony pn Programme
Pfizer (Malaysia) Sdn Bhd Level 10 & 11, Wisma Averis (Tower 2), Bangsar South, No. 8, Jalan Kerinchi, 59200 Kuala Lumpur, Malaysia. Tel: 603-2281 6000 Fax: 603-2281 6388 PP-CMR-MYS-0037-09MARCH2023 A community message by 197801003134 (40131-T) Image used is for illustration purposes only LET'S CONTINUE TO DO OUR PART AND PROTECT OURSELVES, OUR FAMILY, AND OUR COMMUNITY FROM COVID19. Please scan the QR code to find out if you and your family are eligible for a booster vaccine and where you can get one.
Because compliance is important Still goingstrongMONTHLY TABLET © Copyright 2022 DKSH. All rights reserved DKSH Malaysia Sdn Bhd (196101000441 (4476- U)) B-11-01 The Ascent Paradigm, No.1 Jalan SS7/26A Kelana Jaya, 47301 Petaling Jaya, Selangor, Malaysia Phone +60 3 7882 8888, Fax +60 3 7882 8688, www.dksh.com BONBUN140622V1
Thank you for joining us! SEE YOU NEXT YEAR!